Hormonal contraception

Obstetrics and Gynecology

Volumn 112, Issue 3, 2008, Pages 670-684

  Blumenthal, Paul D ^a,c   Edelman, Alison ^b  

^a STANFORD UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CHLORMADINONE; DEPO SC; DESOGESTREL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; GESTAGEN; GESTODENE; HORMONE; LEVONORGESTREL; LOESTRIN 24 FE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORGESTIMATE; NUVA RING; RIFAMPICIN; TAMOXIFEN; UNCLASSIFIED DRUG; CONTRACEPTIVE AGENT;

ACNE; ANTIBIOTIC PROPHYLAXIS; APPETITE; ARTICLE; BLEEDING; BLOOD PRESSURE; BREAST CANCER; COMORBIDITY; DIABETES MELLITUS; DIZZINESS; DRUG SAFETY; EVIDENCE BASED PRACTICE; HAIR LOSS; HEADACHE; HORMONAL CONTRACEPTION; HUMAN; HYPERICUM PERFORATUM; HYPERTENSION; IMPLANT; INTRAUTERINE CONTRACEPTIVE DEVICE; NAUSEA; OBESITY; OILY SKIN; OVULATION INHIBITION; PREGNANCY; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SMOKING; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; VAGINA RING; ADULT; DRUG ADMINISTRATION ROUTE; FEMALE; PROSTHESES AND ORTHOSES; REVIEW;

ADULT; CONTRACEPTIVE AGENTS, FEMALE; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; PROSTHESES AND IMPLANTS;

EID: 55949126231     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31818425b7     Document Type: Article

References (99)

1. Frost JJ, Sonfield A, Gold R, Ahmed F. Estimating the impact of serving new clients by expanding funding for Title X. Guttmacher Institute Occasional Report No 33. November 2006. Available at http://www.guttmacher.org/sections/ index.php?page=reports. Retrieved May 30, 2007.
2. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006;38:91-6.
3. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed.Available at www.who.int/reproductive-health/publications/mec. Retrieved December 4, 2007.
4. Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin No. 73. American College of Obstetricians and Gynecologists. Obstet Gynecol 2006 Jun;107:1453-72.
5. Stewart FH, Harper CC, Ellertson CE, Grimes DA, Sawaya GF, TrussellJ. Clinical breast and pelvic examination requirements for hormonal contraception: current practice vs evidence. JAMA 2001;285:2232-9.
6. Mosher WD, Martinez GM, Chandra A, Abma JC, Wilson SJ. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data 2004;10:1-36.
7. 2003 ACOG News Release. Gallup Survey of Women OB/GYNs. Available at: http://www.acog.org/from-home/publications/press-releases/nr12-09-03.cfm. Retrieved February 4, 2008.
8. TrussellJ, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plan Perspect 1999; 31:64-72, 93.
9. TrussellJ. Contraceptive failure in the United States. Contraception 2004;70:89-96.
10. Sivin I. IUDs are contraceptives, not abortifacients: a comment on research and belief. Stud Fam Plan 1989;20:355-9.
11. Anderson J, Rybo G. Levonorgestrel-releasing IUD in the treatment of menorrhagia. Br J Obstet Gynaecol 1990;97: 1-36.
12. Fedele L, Bianchi S, Raffaelli R, Portuese A, Dorta M. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997; 68:426-9.
13. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid and a levonorgestrel-releasing intrauterine device in the treatment of idiopathic menorrhagia. AmJ Obstet Gynecol 1991;164:879-83.
14. Lockhat FB, Emembolu JO, Konje JC. The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease. Hum Reprod 2004;19: 179-84.
15. Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril 2003;80:305-9.
16. Bragheto A, Caserta N, Bahamondes L, Petta C. Effectiveness of the levonorgesrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception 2007;76:195-9.
17. Gardner FJ, Konje JC, Abrams KR, Brown LJ, Khanna S, Al-Azzawi F, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000;356: 1711-7.
18. Suhonen S, Holmstrom T, Lahteenmaki P. Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy. Acta Obstet Gynecol Scand 1997;76:145-50.
19. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;339:785-8.
20. Grimes DA, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. The Cochrane Database of Systemic Reviews 2000, Issue 2. Art. No.: CD001327.
21. Walsh T, Grimes DA, Frezieres R. Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices. IUD Study Group. Lancet 1998;351:1005-8.
22. White MK, Ory HW, Rooks JB, Rochat RW. Intrauterine device termination rates and the menstrual cycle day of insertion. Obstet Gynecol 1980;55:220-4.
23. Stanback J, Qureshi Z, Nutley T, Sekadde-Kigondu C. Checklist for ruling out pregnancy among family planning clients in primary care. Lancet 1999;354:566.
24. Intrauterine device. ACOG Practice Bulletin No 59. American College of Obstetricians and Gynecologists. Obstet Gynecol 2005;105:223-32
25. Bahamondes L, Monteiro-Dantas C, Espejo-Arce X, Dos Santos Fernandes AM, Lui-Filho JF, Perrotti M, et al. A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants. Hum Reprod 2006;21:466-70.
26. Beerthuizen R, van Beek A, Massai R, Mäkäräinen Hout J, Bennink HC. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod 2000;15:118-22.
27. Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A long term study of the efficacy and acceptability of a single-rod hormonal contraceptive implant (Implanon) in healthy women in China. Eur J Contracept Reprod Health Care 1999;4:85-93.
28. Peralta O, Diaz S, Croxatto H. Subdermal contraceptive implants. Steroid Biochem Molec Biol 1995;53:223-6.
29. Brache V, Faundes A, Johansson E, Alvarez F. Anovulation, inadequate luteal phase and poor sperm penetration in cervical mucus during prolonged use of Norplant implants. Contraception 1985;31:261-73.
30. Croxatto HB, Makarainen L. The pharmacodynamics and efficacy of Implanon: an overview of the data. Contraception 1998;58:91S-7S.
31. Croxatto HB. Mechanisms that explain the contraceptive action of progestin implants for women. Contraception 2002; 65:21-7.
32. Makarainen L, van Beek A, Tuomivaara L, Asplunde B, Coelingh Bennink H. Ovarian function during the use of a single contraceptive implant: Implanon compaed with Norplant. Fertil Steril 1998;69:714-21.
33. Harrison-Woolrych M, Hill R. Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia. Contraception 2005; 71:306-8.
34. Croxatto HB, Urbancsek J, Massai R, et al. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Human Reproduction 1999;14:976-981.
35. Bjarnadottir RI, Gottfredsdottir H, Sigurdardottir K, et al. Comparative study of the effects of a progestogen-only pill containing desogestrel and an intrauterine contraceptive device in lactating women. Br J Obstet Gynaecol 2001;108: 1174-1180.
36. Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon. Contraception 1998;58 (6 suppl):99S-107S.
37. Kiriwat O, Patanayindee A, Koetsawang S, et al. A 4-year pilot study on the efficacy and safety of Implanon, a single rod hormonal contraceptive implant, in healthy women in Thailand. Eur J Contracept Reprod Health Care 1998;3:85-91.
38. Sivin I, Mishell D Jr, Diaz S, Biswas A, Alvarez F, Darney P, et al. Prolonged effectiveness of Norplant capsule implants: a 7-year study. Contraception 2000;61:187-94.
39. Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Guest F, et al. Contraceptive technology. 17th ed. New York (NY): Ardent Media; 1998.
40. Speroff L, Darney PD. A clinical guide for contraception. 2nd ed.Baltimore (MD): Williams and Wilkins; 1996.
41. Kaunitz AM. Injectable contraception. Clin Obstet Gynecol 1989;356-68.
42. Kaunitz AM. Long-acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol 1994; 170:1543-9.
43. Jain J, Dutton C, Nicosia A, Wajszczuk C, Bode F, Mishell D. Pharmacokinetics, ovulation suppression, and return to ovulation following a lower dose subcutaneous formulation of Depo Provera. Contraception 2004;70:11-8.
44. Kaunitz AM, Mishell DR. Progestin-only contraceptives: current perspectives and future directions. Dialog Contracept 1994;4:1-5.
45. Arias R, Jain JK, Brucker C, Ross D, Ray A. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. Contraception 2006;74: 234-8.
46. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception 2003;68:75-87.
47. Depot medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Inter J Cancer 1991;49:186-90.
48. Cullins VE. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate. J Reprod Med 1996; 41:428-33.
49. Mattson RH, Cramer JA, Caldwell BV, Siconolfi BC. Treatment of seizures with medroxyprogesterone acetate: preliminary report. Neurology 1984;34:1255-8.
50. Legardy JK, Curtis KM. Progestin-only contraceptive use among women with sickle cell anemia: a systematic review. Contraception 2006;73:195-204.
51. de Abood M, de Castillo Z, Guerrero F, Espino M, Austin KL. Effect of depoprovera or microgynon on the painful crises of sickle cell anemia patients. Contraception 1997;56: 313-6.
52. Cullins VE. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate. J Reprod Med 1996; 41:428-33.
53. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 1991;303:13-6.
54. Cundy T, Farquhar CM, Cornish J, Reid IR. Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women [see Comments]. J Clin Endocrinol Metab 1996;81:1014-7.
55. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski A. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 1996;129:671-6.
56. Kaunitz AM. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians. Int J Fertil Womens Med 1998;43:73-83.
57. World Health Organization. WHO statement on hormonal contraception and bone health. July 2005 Available at: http://www.who.int/reproductivehealth/ family-planning/bone-health. html. Retrieved July 28, 2008.
58. Bachrach L, Cundy T, Ott S. Depot medroxyprogesterone acetate in teens: a risk for bone health? Pediatrics 2000;106: 1137-8.
59. Stanwood NL, Eastwood K, Carletta A. Self-injection of monthly combined hormonal contraceptive. Contraception 2006 Jan;73:53-5.
60. Stanback J, Mbonye AK, Bekiita M. Contraceptive injections by community health workers in Uganda: a nonrandomized community trial. Bull World Health Organ 2007;85:768-73.
61. van den Heuval MW, van Bragt AJM, Alnabawy KK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005;72:168-74.
62. Westhoff CL. Oral contraceptives and thrombosis: An overview of study methods and recent results. Am J Obstet Gynecol 1998;179:538-42.
63. Moghissi KS, Syner FN, McBride LC. Contraceptive mechanism of microdose norethindrone. Obstet Gynecol 1973;41: 585-94.
64. Elstein M, Morris SE, Groom GV, Jenner DA, Scarisbrick JJ, Cameron EH. Studies on low-dose oral contraceptives: cervical mucus and plasma hormone changes in relation to circulating D-norgestrel and 17-ethynyl estradiol concentrations. Fertil Steril 1976;27:892-8.
65. Huggins GR, Cullins VE. Fertility after contraception or abortion. Fertil Steril 1990;54:559-73.
66. Hormonal contraception. ACOG Technical Bulletin No. 198. Int J Gynaecol Obstet 1995;48:115-26
67. Westhoff C, Morroni C, Kerns J, Murphy PA. Bleeding patterns after immediate versus conventional oral contraceptive initiation: a randomized controlled trial. Fertil Steril 2003;79:322-9.
68. Verhoeven C, Dieben T. The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage. Contraception 2004;69:197-9.
69. Verhoeven C, van den Heuval MW, Mulders TMT, Dieben T. The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. Contraception 2004;69:129-32.
70. Edelman A, Gallo M, Nichols M, Jensen JT, Schulz K, Grimes D. Continuous or extended cycle vs cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. Cochrane Database of Systematic Reviews 2005; Issue 3. Art. No.: CD004695.
71. Sulak PJ, Kuehl TJ, Coffee A, Willis S. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Am J Obstet Gynecol 2006;195:935-41.
72. Edelman AB, Koontz SL, Nichols MD. Continuous oral contraceptives: are bleeding patterns dependent on the hormones given? Obstet Gynecol 2006;107:657-65.
73. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 μg (Loestrin 24 Fe). Contraception 2007;16-22.
74. Westhoff CL. Oral contraceptives and thrombosis: An overview of study methods and recent results. Am J Obstet Gynecol 1998;179:538-42.
75. Khader YS, Rice J, Abueita O. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception 2003;68:11-7.
76. Sidney S, Siscovick DA, Petitti DB, Schwartz SM, Quesenberry CP, Psaty BM, et al. Myocardial infartction and use of low-dose oral contraceptives. A pooled analysis of 2 US studies. Circulation 1998;98:1058-63.
77. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997;349:1202-9.
78. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Hae-morrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996;348:505-10.
79. Curtis K, Mohllajee A, Peterson HB. Use of oral contraceptives among women with migraine and nonmigrainous headaches: a systematic review. Contraception 2006;73:189-94.
80. Jick SS, Kaye JA, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgesstimate and 35 micrograms of ethinyl estradiol. Contraception 2006;73: 223-8.
81. Jick S, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol. Contraception 2007;76:4-7.
82. ColeJA, Norman H, Doherty M, Walker A. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007;109: 339-46.
83. Holt VL, Cushing-Haugen KL, DarlingJR. Body weight and risk of oral contraceptive failure. Obstet Gynecol 2002;99: 820-7.
84. Holt VL, Scholes D, Wickland KG, Cushing-Haugen KL, Darling JR. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 2005;105:46-52.
85. Nightingale AL, Lawrenson RA, Simpson EL, Williams TJ, Farmer KD. The effects of age, body mass index, smoking, and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2005;5:265-74.
86. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. JAMA 2003;89:493-8.
87. Oral contraceptive use and the risk of endometrial cancer. The Centers for Disease Control Cancer and Steroid Hormone Study. JAMA 1983;249:1600-4.
88. Oral contraceptive use and the risk of ovarian cancer. The Centers for Disease Control Cancer and Steroid Hormone Study. JAMA 1983;249:1596-9.
89. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative breast cancer reanalysis of individual data on 53, 297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
90. Therapeutic uses of oral contraceptives. Dialogues Contracept 1991;3:4-6.
91. McCann MF, Lotter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994:50:SI195.
92. Chi IC. The progestin-only pills and the levonorgestrel-releasing IUD: two progestin-only contraceptives. Clin Obstet Gynecol 1995;38:872-89.
93. Broome M, Fotherby K. Clinical experience with the proges-togen-only pill as a contraceptive method. Br J Fam Plann 1990;16-84.
94. von Hertzen H, Piaggio G, Ding J, Chen J, Song S, Bartfai G, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre, randomised trial. Lancet 2002;360:1803-10.
95. Piaggio G, von Hertzen H, Grimes DA, Van Look PF. Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Lancet 1999;353:721.
96. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1998;352:428-33.
97. Raine T, Harper C, Leon K, Darney P. Emergency contraception: advance provision in a young, high-risk clinic population. Obstet Gynecol 2000;96:1-7.
98. Trussell J, Rodriguez G, Ellertson C. New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception 1998;5:363-9.
99. Creinin MD. A reassessment of efficacy of the Yuzpe regimen of emergency contraception. Hum Reprod 1997;12:496-8.